Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmaceutica Remedia Buyback Yield % Related Terms
Farmaceutica Remedia Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Farmaceutica Remedia's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:RMAH vs MCK, COR, CAH: Buyback Yield % Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia Buyback Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmaceutica Remedia (BSE:RMAH) has a Buyback Yield % of 0.00 as of Jul. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Farmaceutica Remedia and its competitors. Over the past decade, Farmaceutica Remedia's Buyback Yield % has ranged from 0.76 to 2.54. According to the industry distribution chart, Farmaceutica Remedia ranks #999999 out of 39 companies in the Medical Distribution industry.
Is Farmaceutica Remedia's Buyback Yield % too high?
Farmaceutica Remedia's current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 2.54. Based on the distribution chart, Farmaceutica Remedia ranks #999999 out of 39 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Farmaceutica Remedia has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Buyback Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #999999 out of 39 companies for Buyback Yield %. This places Farmaceutica Remedia in the lower half of its industry. Historically, Farmaceutica Remedia's own Buyback Yield % has ranged from 0.76 to 2.54 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Distribution company?
A good Buyback Yield % depends on the Medical Distribution industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Farmaceutica Remedia and its competitors. Farmaceutica Remedia's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Based on GuruFocus' analysis, Farmaceutica Remedia (BSE:RMAH) is currently considered Modestly Overvalued. The stock's GF Value™ is lei0.79, compared to a current price of lei0.88 — trading 11.9% above its estimated fair value. The current Buyback Yield % is 0.00. Farmaceutica Remedia's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Farmaceutica Remedia (BSE:RMAH), the current Buyback Yield % is 0.00 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (BSE:RMAH) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.88 is trading 11.9% above its estimated GF Value™ of lei0.79.
GuruFocus considers Farmaceutica Remedia to be Modestly Overvalued.
Key valuation signals for BSE:RMAH:
Buyback Yield %: 0.00
GF Value™: lei0.79 vs. price of lei0.88 (11.9% above fair value)
No single metric tells the full story. See the BSE:RMAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
58GF Score
Get the complete analysis for BSE:RMAH
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:RMAH has been successfully added to your 
